Morphine decreases clopidogrel concentrations and effects: A randomized, double-blind, placebo-controlled trial

Journal of the American College of Cardiology

Volumn 63, Issue 7, 2014, Pages 630-635

  Hobl, Eva Luise ^a   Stimpfl, Thomas ^a   Ebner, Josef ^a   Schoergenhofer, Christian ^a   Derhaschnig, Ulla ^a   Sunder Plassmann, Raute ^a   Jilma Stohlawetz, Petra ^a   Mannhalter, Christine ^a   Posch, Martin ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

clopidogrel; drug interaction; morphine

Indexed keywords

CLOPIDOGREL; MORPHINE; MORPHINE SULFATE; PLACEBO; ADENOSINE DIPHOSPHATE; DRUG METABOLITE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; FATIGUE; FEMALE; FUNCTION TEST; HEADACHE; HOT FLUSH; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHEAR RATE; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA; DRUG EFFECT; DRUG METABOLISM; DRUG TREATMENT FAILURE; LOADING DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION;

CLOPIDOGREL; DRUG INTERACTION; MORPHINE;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; MORPHINE; TICLOPIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896694643     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.10.068     Document Type: Article

References (18)

1. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
2. J.L. Anderson, C.D. Adams, and E.M. Antman et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e179 e347
3. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
4. T.J. Meine, M.T. Roe, and A.Y. Chen et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative Am Heart J 149 2005 1043 1049
5. G. Parodi, R. Valenti, and B. Bellandi et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
6. W.S. Nimmo, R.C. Heading, J. Wilson, P. Tothill, and L.F. Prescott Inhibition of gastric emptying and drug absorption by narcotic analgesics Br J Clin Pharmacol 2 1975 509 513
7. P.A. Gurbel, K.P. Bliden, and K. Butler et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
8. L. Bonello, M. Pansieri, and J. Mancini et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
9. J.M. Siller-Matula, G. Christ, I.M. Lang, G. Delle-Karth, K. Huber, and B. Jilma Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay J Thromb Haemost 8 2010 351 359
10. I. Fuchs, M. Frossard, A. Spiel, E. Riedmuller, A.N. Laggner, and B. Jilma Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS J Thromb Haemost 4 2006 2547 2552
11. M. Takahashi, H. Pang, K. Kawabata, N.A. Farid, and A. Kurihara Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS J Pharm Biomed Anal 48 2008 1219 1224
12. T. Gremmel, C.W. Kopp, and D. Seidinger et al. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests Int J Cardiol 166 2013 126 131
13. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
14. N.A. Farid, C.D. Payne, and D.S. Small et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently Clin Pharmacol Ther 81 2007 735 741
15. J.M. Siller-Matula, K. Huber, and G. Christ et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis Heart 97 2011 98 105
16. P.A. Gurbel, and U.S. Tantry Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 125 2012 1276 1287
17. W. Hochholzer, D. Trenk, and D. Frundi et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564
18. F. Bochner, and J.V. Lloyd Aspirin for myocardial infarction. Clinical pharmacokinetic considerations Clin Pharmacokinet 28 1995 433 438